Диссертация (1140223), страница 28
Текст из файла (страница 28)
Galectin-3: an open-ended story // Biochim BiophysActa. 2006; 1760:616–635.67. Duncan E.R., Crossey P.A., Walker S., Anilkumar N., Poston L., Douglas G. et al.Effect of endothelium-specific insulin resistance on endothelial function in vivo //Diabetes. 2008; 57(12): 3307-3314.68. Ehara S., Ueda M., Naruko T., Haze K., Itoh A., Otsuka M. et al. Elevated levels oflow density lipoprotein show a positive relationship with the severity of acute coronarysyndromes // Circulation. 2001; 103:1955—1960.69. Eikelis N., Schlaich M., Aggarwal A., Kaye D. and Esler M. Interactions betweenleptin and the human sympathetic nervous system // Hypertension.
2003; 41(5):1072–1079.70. Fallo F., Dalla Pozza A., Sonino N., Lupia M., Tona F., Federspil G. et al. Non–alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction inessential hypertension // Nutr Metab Cardiovasc Dis. 2009; 19(9):646–653.71.
Fantuzzi G., Mazzone T. Adipose tissue and atherosclerosis: Exploring theconnection // Arterioscler Thromb Vasc Biol. 2007; 27:996-1003.72. Ferrara LA, Cardoni O, Mancini M, Zanchetti A. Metabolic syndrome and leftventricular hypertrophy in a general population. Results from the Gubbio Study // J HumHypertens. 2007; 21(10):795-801.73. Fruhbeck G., Gomes - Ambrosi J. Muruzabal F., Burrell M. The adipocyte -: a modelfor integration of endocrine and metabolic signaling in energy metabolism regulation //Am. J Physiol Endocrinol Metab.
2001; 280:827-847.74. Fruchbeck G. Intracellular signalling pathways activated by leptin // Biochem. J.2006; 393:7–20.75. Frystyk J., Berne C., Berglund L., Jensevik K, Flyvbjerg A, Zethelius B. Serumadiponectin is a predictor of coronary heart disease: a population-based 10-year followup study in elderly men // J Clin Endocrinol Metab. 2007; 92:571–576.76. Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, et al. DJ.Leptin can induce proliferation, differentiation, and functional activation of hemopoieticcells // Proc Natl Acad Sci USA.
1996, 93:14564–14568.16177. Garg S., Narula J., Chandrashekhar Y. Apoptosis and heart failure: clinical relevanceand therapeutic target // J Mol Cell Cardiol. 2005; 38:73–9.78. Gastaldelli A., Kozakova M., Højlund K., Flyvbjerg A., Favuzzi A., Mitrakou A.,Balkau B. Fatty liver is associated with insulin resistance, risk of coronary heart disease,and early atherosclerosis in a large European population // Hepatology. 2009; 49:15371544.79. Gokce N., Keaney J.F. Jr., Hunter L.M., Watkins M.T., Nedelijkovic Z., MenzoianJ.O.
et al. Predictive value of non-invasively determined endothelial dysfunction forlong-term cardiovascular events in patients with peripheral vascular disease // J. Am.Coll. Cardiol. 2003; 41:1769-1775.80. Goldstein BJ, Mahadev K, Wu X. Redox paradox: insulin action is facilitated byinsulin-stimulated reactive oxygen species with multiple potential signalic targets //Diabetes.
2005; 54:311-321.81. Gullicksen P.S., Della-Fera M.A. and Baile C.A. Leptin-induced adipose apoptosis:Implications for body weight regulation // Kluwer Academic Publishers. 2003; 8:327–335.82. Hamaguchi M., Kojima T., Takeda N., Nagata C., Takeda J., Sarui Het et al.Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease // World JGastroenterol. 2007; 13:1579–1584.83. Haring R., Wallaschofski H., Nauck M., Dorr M., Baumeister S.E., Volzke H.Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevatedserum gamma-glutamyl-transpeptidase levels // Hepatology.
2009; 50:1403-1411.84. Haruta T., Uno T., Kawahara J., Takano A., Egawa K., Sharma P.M., et al. Arapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation andproteasomal degradation of insulin receptor substrate-1 // Molecular Endocrinology.2000; 14(6):783–794.85. Hashimoto N., Kanda J., Nakamura T., Horie A., Kurosawa H., Hashimoto T.
et al.Association of hypoadiponectinemia in men with early onset of coronary heart diseaseand multiple coronary artery stenosis // Metabolism. 2006; 55:1653–1657.16286. Hatting M, Zhao G, Schumacher F, Sellge G, Masaoudi MA, Gabler N et al.Hepatocyte Caspase-8 is an Essential Modulator of Steatohepatitis in Rodents //Hepatology. 2013; 57(6):2097–2554.87. He L., Lemasters J.J. Regulated and unregulated mitochondrial permeabilitytransition pores: a new paradigm of pore structure and function? // FEBS Lett. 2002;512:1-7.88. Henriksen E.
J., Diamond-Stanic M. K., and Marchionne E. M. Oxidative stress andthe etiology of insulin resistance and type 2 diabetes // Free Radical Biology andMedicine. 2011; 51(5):993–999.89. Hoyer K.K., Pang M, Gui D, Shintaku IP, Kuwabara I, Liu FT et al. An antiapoptoticrole for galectin-3 in diffuse large B-cell lymphomas // Am J Pathol. 2004; 164:893-902.90. http://www.angioscan.ru.91. http://www.idf.org/metabolic-syndrome.92.
Huang C-Y, Lee S-D. Possible pathophysiology of heart failure in obesity: Cardiacapoptosis // BioMedicine. 2012; 2(1):36-40.93. Hutley L. Prins J. Fat as an endocrine organ: relationship to the metabolic syndrome //Amer J Med Sciences. 2005; 330(6):280-289.94. Iacobellis G., Assael F., Ribaudo M.C., Vecci E., Tiberti C., Zappaterreno A. et al.Epicardial fat from echocardiography: a new method for visceral adipose tissueprediction // Obes Res. 2003; 11(2):304–310.95. Iacobellis G., Ribaudo M.C. Correlation between insulin resistance and leftventricular mass in uncomplicated obesity // Diabetologia.
2001; 44:701.96. Iacobellis G., Willens H.J., Barbaro G., Sharma A.M. Threshold values of high-riskechocardiographic epicardial fat thickness // Obesity (Silver Spring). 2008; 16(4):887892.97. Iacobini C., Menini S., Ricci C.
Fantauzzi C.B., Scipioni A., Salvi L. et al. Galectin-3ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3in liver // Journal of Hepatology. 2011; 54:975–983.98. Imajo K., Fujita K., Yoneda M., Nozaki Y., Y. Ogawa, Shinohara Y., et al.Hyperresponsivity to low-dose endotoxin during progression to nonalcoholicsteatohepatitis is regulated by leptin-mediated signaling // Cell Metab.
2012, 16:44–54.16399. Iredale J. P. Models of liver fibrosis: exploring the dynamic nature of inflammationand repair in a solid organ // J Clin Invest. 2007; 117(3):539–548.100. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation// Best Pract Res Clin Endocrinol Metab. 2005; 19 (4): 547–66.101. Kamata, H., and Hirata, H. Extracellular stimuli elicit a variety of responses, such ascell proliferation and differentiation, through the cellular signalling system // Cell. Signal.1999; 11:1-14.102. Kanda T., Nakamura E., Moritani T., Yamori Y. Arterial pulse wave velocity andrisk factors for peripheral vascular disease // Eur J Appl Physiol. 2000; 82(l-2):1-7.103. Kannel W.B., McGee D.L.
Diabetes and cardiovascular disease: the FraminghamStudy // JAMA. 1979; 241: 2035-2038.104. Kaplowits N. Mechanism of liver cell injury // J Hepatol. 2000; 32(1):39–47.105. Kieffer T, Habener JF. The adipoinsular axis: effects of leptin on pancreatic b-cells// Am J Physiol. 2000; 278:1-14.106. Kontrogianni-Konstantopoulos A., Benian G., and Granzier H. Advances in musclephysiology and pathophysiology // Journal of Biomedicine and Biotechnology. 2010;Article ID 780417, 1 pages.107. Kwang KK, Sang Min Park, Michael J.
Quon. Leptin and Cardiovascular Disease //AHA. 2008; 117:3238-3249.108. Lau D.C.W., Dhillon B., Yan H., Szmitko P. E. and S. Verma. Adipokines:molecular links between obesity and atherosclerosis // The American Journal ofPhysiology—Heart and Circulatory Physiology. 2005; 288(5):2031–2041.109. Laybutt DR, Kaneto H, Hasenkamp W, Grey S, Jonas JC, Sgroi DC. et al. Increasedexpression of antioxidant and antiapoptotic genes in islets that may contribute to β-cellsurvival during chronic hyperglycemia // Diabetes.
2002; 51:413-423.110. Lazo M., Clark J. The epidemiology of nonalcoholic fatty liver disease: a globalperspective // Semin Liver Dis. 2008; 28(4):339–350.111. Lee S.D., Tzang B.S., Kuo W.W., Lin Y.M., Yang A.L., Chen S.H. et al. Cardiacfas receptor-dependent apoptotic pathway in obese Zucker rats // Obesity (Silver Spring).2007;15(10):2407-2415.164112. Li C.P., Li J.H., He S.Y., Li P., Zhong X.L. Roles of Fas/Fasl, Bcl-2/Bax, andCaspase-8 in rat nonalcoholic fatty liver disease pathogenesis // Genet Mol Res.
2014;13(2):3991-3999.113. Li SY, Sigmon V.K., Babcock S.A. Advanced glycation endproduct induces ROSaccumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in humancardiac myocytes // Life Sci. 2007; 80:1051–1056.114. Lieb W., Sullivan L. M., Harris T.B., Roubenoff R, Benjamin EJ, Levy D. et al.Plasma leptin levels and incidence of heart failure, cardiovascular disease, and totalmortality in elderly individuals // Diabetes Care. 2009; 32 (4):612–616.115. Lin H.M., Moon B.K., Yu F.
and Kim H.R. Galectin-3 mediates genisteininducedG(2)/M arrest and inhibits apoptosis // Carcinogenesis. 2000; 21:1941-1945.116. Lioudaki E., Ganotakis E.S., Mikhailidis D.P. Liver enzymes: potentialcardiovascular risk markers? // Curr Pharm Des. 2011; 17:3632-3643.117. Liu F., Patterson R.J., Wang J.L. Intracellular function of galectins // BBA GeneralSubjects. 2002; 1572(2-3):263–273.118. Lombardi R., Tonella T., Massari F., Valenti L., Bertelli C., Burdick L. et al.Echocardiographic epicardial fat thickness in non alcoholic fatty liver disease: a possiblemarker of metabolic syndrome and early vascular damage // J Diabet. 2011; 3:201.119.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
